Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.
Core Business and Projects
- SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
- SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
- SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
- SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.
Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.
Financial Condition and Partnerships
Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.
For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Silo Pharma (OTCQB: SILO) has entered a sponsored research agreement with Columbia University to explore options for licensing Alzheimer’s therapeutic assets. Under the leadership of Dr. Christine Ann Denny, the initiative focuses on understanding molecular mechanisms linked to Alzheimer’s disease and memory retrieval. With 5.8 million Americans affected by Alzheimer’s, this collaboration aims to develop innovative treatments using psychedelic compounds, potentially providing significant improvements in cognitive health.
Silo Pharma (OTCQB: SILO) has entered a research agreement with Columbia University focused on developing treatments for Alzheimer’s disease. This partnership involves Dr. Christine Ann Denny, who studies the molecular mechanisms of memory and learning. Silo has the option to license certain assets related to this research, which aims to explore the therapeutic potential of ketamine for improving memory retrieval and addressing cognitive decline. The agreement represents a significant step in Silo's efforts to provide innovative solutions for patients suffering from Alzheimer’s and related conditions.
Silo Pharma (OTCQB: SILO) announced that its joint venture partner, Zylo Therapeutics, received DEA approval to develop Z-pod technology with Ketamine. CEO Eric Weisblum expressed optimism about creating a transdermal Ketamine therapeutic using this patented technology, which may also deliver Psilocybin in a controlled manner. This development aims to provide innovative solutions for patients suffering from depression, PTSD, Parkinson’s, and other neurological disorders. Updates on this partnership are anticipated as milestones are achieved.
Silo Pharma, Inc. (OTCQB: SILO) announced the filing of three Patent Cooperation Treaty (PCT) applications aimed at protecting its intellectual property related to the central nervous system delivery of unique anti-inflammatory therapeutics combined with psilocybin. This step is part of the company’s commitment to research and development in the biopharmaceutical space, specifically targeting conditions like depression and PTSD. The applications focus on the therapeutic potential of psychedelics and anti-inflammatory drugs, expanding possible treatment options for various neurological disorders.
On August 11, 2021, Silo Pharma (OTCQB:SILO) announced that its partner, ZYLO Therapeutics, successfully completed its first inspection with the SC Board of Pharmacy. This milestone enables progress with the Department of Health and Environmental Control towards developing a transdermal Ketamine therapeutic leveraging patented Z-Pod® technology. CEO Eric Weisblum emphasized the significance of this step, highlighting the potential for controlled, time-released delivery of Ketamine or Psilocybin.
Silo Pharma (OTCQB:SILO) announced a significant development in its product pipeline, receiving a notice of allowance for a patent from the United States Patent Office pertaining to its Central Nervous System Homing Peptide. This novel peptide aims to enhance the delivery of psychedelics, including Psilocybin, for therapeutic applications. CEO Eric Weisblum expressed optimism about expanding their intellectual property portfolio to cover markets for potential therapeutic applications, addressing conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) will engage in a nationwide media tour on July 22, aimed at raising awareness about psychedelic medicines and their potential therapeutic benefits for conditions such as mental illness and chronic pain. Sponsored by Radio Media LLC, the tour will feature Dr. Josh Woolley, MD, PhD, discussing ongoing research in psychedelic therapy. The broadcast will reach various stations across the U.S., with recordings available on Silo Pharma's website post-event.
Silo Pharma (OTCQB: SILO) has entered into a Scientific Research Agreement with the University of Maryland, Baltimore, to investigate the efficacy of a novel peptide, ART-1, for delivering dexamethasone to treat rheumatoid arthritis. This study will utilize peptide-guided liposomes to potentially enhance the drug's efficacy and reduce toxicity. CEO Eric Weisblum emphasized the importance of this milestone for accessing a significant market and improving therapeutic targeting. The company aims to develop a technology platform adaptable for other drugs, enhancing treatment options for various conditions.
Silo Pharma has extended its exclusive option agreement with the University of Maryland, Baltimore to investigate novel joint-homing peptides aimed at treating rheumatoid arthritis. This extension allows Silo more time to evaluate a potentially transformative therapeutic platform that could enhance drug delivery for traditional and psychedelic treatments, which may improve efficacy while reducing toxicity. CEO Eric Weisblum emphasized the significance of this technology for targeted therapy delivery.
Silo Pharma, Inc. (OTCQB: SILO) has entered a Scientific Research Agreement with the University of California San Francisco (UCSF) to explore the effects of psilocybin on inflammatory markers in patients with Parkinson's, Bipolar disorder, and chronic back pain. This agreement will utilize four other planned clinical trials by UCSF. CEO Eric Weisblum emphasized the potential of psilocybin to reduce inflammation related to these conditions, which may improve treatment outcomes. The study will be conducted at UCSF's Translational Psychedelic Research Program, focusing on the impact of psychedelics on various disorders.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What does Silo Pharma, Inc. specialize in?
What are Silo Pharma's leading development programs?
Who are Silo Pharma's research partners?
What recent achievements has Silo Pharma announced?
How does Silo Pharma aim to impact the healthcare industry?
Where can I find more information about Silo Pharma?
What is the significance of Silo Pharma's SP-26 program?
What progress has been made with the SPC-15 program?
What conditions does Silo Pharma aim to address with its treatments?